Medtronic received information that at approximately seven months and two weeks post-implant this bioprosthetic aortic valve was explanted due to a genetic sub-aortic membrane that was causing suture line dehiscence.In addition it was reported that the patient was medically non-compliant after the implant, a consistent cocaine abuser, and the patient had a very small root and partially obstructed left ventricular outflow tract (lvot).The valve was replaced with another bioprosthetic aortic valve.There were no performance allegations or further adverse patient effects reported.
|
A review of the device history record (dhr) was performed for this valve, there were no non-conformances identified in manufacturing process (raw materials, manufacturing time period, or packaging and labeling) that could be related to this event.This device was manufactured per approved and released manufacturing processes and met all applicable manufacturing specifications prior to release for distribution.There were no alleged deficiencies related to product quality/performance or manufacturing process.Without the return of the valve, a root cause of the event was unable to be determined.(b)(4).
|